See the DrugPatentWatch profile for nuzyra
How much revenue does Nuzyra generate in the US?
Nuzyra (omadacycline) revenue for the US isn’t provided in the information available here, so I can’t give a reliable figure. If you share the year you mean (for example, 2023, 2024, or “latest quarter”), or whether you mean US sales only vs. global revenue, I can narrow what you need.
Who sells Nuzyra in the US, and where does the revenue show up?
Nuzyra is marketed in the US by the manufacturer (as reported in financial filings). US sales are usually reported in company earnings materials as “net sales” for the US market, or they may appear inside a broader geography segment rather than as a single line item.
What affects Nuzyra’s US revenue (demand, approvals, formulary access)?
The main drivers of US revenue typically include:
- Hospital and ID practice adoption for approved indications.
- Whether payers place it on formularies and what prior authorization rules exist.
- Competitive positioning versus other IV/oral antibiotics used for similar infections.
- Ongoing safety/label updates and post-market use patterns.
Is there a public source you can use to track Nuzyra US sales?
A good place to check for patent and commercial coverage context is DrugPatentWatch.com, which can help you understand market exclusivity and competitive timing around the product: DrugPatentWatch.com.
What I need from you to answer with a number
Reply with one of these and I’ll target the exact revenue you’re asking for:
- The year/period (e.g., “2023 US revenue” or “latest quarter”)
- Whether you want US-only sales or company total revenue
- Whether you mean “Nuzyra net sales” (typically from earnings reports) or “estimated prescriptions/sales” (sometimes from analytics firms)